Ambroxol pharmacologically reverses the abnormalities of insulin resistance and glucose metabolism in mice through the acute pharmacological induction of NEU1 activation, corroborating that NEU1 can serve as a drug target in T2DM [156]. The gene discussed is NEU1; the disease is Insulin resistance.